About the Journal
The Journal of Antimicrobial Chemotherapy is a journal of the British Society for Antimicrobial Chemotherapy (BSAC) and is among the foremost international journals in antimicrobial research. Our readership includes representatives of academia, industry and health services, and includes those who are influential in formulary decisions.
The Journal publishes original articles on lab-based and clinical use of antimicrobials including antibacterial, antiviral, antifungal, and antiprotozoal agents. We particularly welcome manuscripts on:
-
the practice of evidence-based medicine relating to antimicrobials (clinical trials, systematic reviews and meta-analyses)
-
antimicrobial treatment (pharmacokinetics, pharmacodynamics and prescribing practices)
-
the action of antimicrobial agents and the mechanisms, genetics and epidemiology of antimicrobial resistance
-
antimicrobial stewardship
-
the genetic basis of antimicrobial resistance.
We encourage our authors to:
-
offer evidence-based synthesis of knowledge and data useful for clinical practice
-
analyse, reflect and comment on the current state of the art and practice
-
consolidate our knowledge of antimicrobial agents and their use
-
consider the future of antimicrobial chemotherapy
In addition to the wealth of primary papers, the Journal also publishes review articles offering in-depth discussion on matters of topical concern. Lively leading articles offer incisive coverage of recent advances and controversies.
Other sections include:
-
For debate: International comment on contentious issues and ideas
-
Antimicrobial practice: Articles on practical prescribing and formulary issues
-
Correspondence: A section for scientists to present early observations of their work and to comment on published articles
The Journal publishes between two and eight supplements each year. These include Working Party reports of the British Society for Antimicrobial Chemotherapy, and original publications on pre-clinical and clinical aspects of drugs in development or the role of established drugs in specific therapeutic areas.
Publishing with Journal of Antimicrobial Chemotherapy
As a Journal of Antimicrobial Chemotherapy author, you will be part of a prestigious tradition of excellence. For almost 50 years we have published the world’s finest minds, shaping and developing important and rigourous research and scholarship.
A global audience for your work
The Journal of Antimicrobial Chemotherapy connects powerful ideas with the widest audience to give your research the greatest possible impact. Our top regions for readership are North America, Europe, and China.
-
3,320,000+ article downloads in 2022
-
98% of articles cited within two years of publication
-
2023 Impact Factor: 3.9
-
2023 CiteScore: 9.2
-
Publishing in JAC gets your work noticed! 95% of articles published in 2022 have been mentioned online, including in news outlets, social media, patents, and government policy documents*.
-
Indexed in PubMed, Web of Science, and Scopus (See full list below)
*Source: Altmetric, as of June 2024
Efficient and transparent editorial processes
When you submit a manuscript to Journal of Antimicrobial Chemotherapy, you can be confident that the support of our editorial team and our rigourous peer review process will ensure that your research findings are published at their best.
Editorial decision-making is managed by a team of active researchers, clinicians, and academics whose expertise represents the antimicrobial research community.
Manuscript processing times:
- Median time from submission to first decision: 14 days
- Average days in review: 14 days
- Average days from acceptance to advance access publication: 18 days
Abstracting and Indexing Services
The Journal of Antimicrobial Chemotherapy is covered by the following major indexing services:
- MEDLINE
- PubMed
- Scopus
- Science Citation Index
- Web of Science
- CABI
- And a range of specialist indices
Journal CiteScore
- 9.2
Impact Factor and Ranking
| Year | Impact Factor | Si: Infectious Diseases | Si: Microbiology | Si: Pharmacology and Pharmacy |
|---|---|---|---|---|
| 2023 | 3.9 | 32 out of 132 | 56 out of 161 | |
| 2022 | 5.2 | 29 out of 96 | 38 out of 135 | 56 out of 277 |
| 2021 | 5.758 | 32 out of 94 | 39 out of 136 | 54 out of 279 |
| 2020 | 5.790 | 14 out of 93 | 26 out of 136 | 43 out of 276 |
| 2019 | 5.439 | 10 out of 93 | 24 out of 134 | 22 out of 270 |
| 2018 | 5.113 | 8 out of 89 | 22 out of 133 | 22 out of 267 |
| 2017 | 5.217 | 8 out of 88 | 19 out of 125 | 19 out of 261 |
| 2016 | 5.071 | 9 out of 84 | 19 out of 124 | 23 out of 256 |
| 2015 | 4.919 | 9 out of 83 | 19 out of 123 | 20 out of 253 |
| 2014 | 5.313 | 8 out of 78 | 17 out of 119 | 17 out of 254 |
| 2013 | 5.439 | 6 out of 70 | 17 out of 119 | 17 out of 254 |
| 2012 | 5.338 | 7 out of 69 | 16 out of 116 | 18 out of 260 |
| 2011 | 5.068 | 7 out of 70 | 18 out of 112 | 20 out of 261 |
| 2010 | 4.659 | 9 out of 58 | 19 out of 107 | 27 out of 249 |
| 2009 | 4.352 | 7 out of 57 | 17 out of 94 | 32 out of 236 |
| 2008 | 4.328 | 8 out of 51 | 17 out of 91 | 30 out of 216 |
| 2007 | 4.038 | 9 out of 50 | 16 out of 94 | 30 out of 205 |
| 2006 | 3.891 | 11 out of 47 | 17 out of 88 | 37 out of 199 |
Latest information taken from the Journal Citation Reports™ from Clarivate, 2024.
